Increase of effectiveness of the arterial hypertension treatment is still a topical problem of medicine and pharmacy because the causes of this disease, in spite of intensive research in this area, are still unknown [5].
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Based on medical statistics data the role of some factors ("risk factors"), such as heredity, age, sex, nutritional peculiarities, weight and others, which can influence on the arterial hypertension development was determined [2] .
The results of the study not only demonstrate dependence of cardiovascular pathology development on the arterial pressure level (АТ), but also allow to evaluate quantitatively the contribution of the systolic (АТS) and diastolic (АТD) arterial pressure to the risks degree [10] . Usually, АТS increases continually with age and is a strong, independent, but variable index of cardiovascular complications of hypertension. Underestimation of its value leads to underestimation of the prevalence of hypertension and untimely prescription of antihypertensive medicines.
Most studies indicate the promising use of rational combinations of diuretics and β-adrenoreceptor antagonists (in low doses) that provide the additive effect, as well as the use of drugs with multiple mechanisms of activity to reach the target level of АТ.
As the alternative in regards to the mentioned above the medicines based on pyrol[3,2,1-ij]quinoline may be applied for the treatment of hypertension [11] . They do not lead to water and electrolyte imbalance and do not cause the secondary hypertension, as well as exhibit the diuretic activity.
At the Pharmaceutical Chemistry Department of the NUPh 4-methoxyanilide of 1-hydroxy-3-oxy-5,6-dihydrо-3Н-pyrol[3,2,1-ij]quinoline-2-carbolic acids under the conditional name of chemopyrone was synthesized. This compound is practically nontoxic and exhibits the expressed diuretic activity [12] .
The aim of the present study was to study the effect of the chemopyrone substance on the arterial pressure under conditions of prophylactic application on the experimental model of induced hypertension.
Materials and Methods
The research was conducted on nonlinear white male rats weighting 180-230 g. The effect of the chemopyrone substance on the arterial pressure was studied both on intact animals and on the background of Mesatonuminduced hypertension.
Mesatonum stimulates postsynaptic α 1 -adrenoreceptor antagonists and increases percussive emission, thereby, rises systolic and diastolic АТ by decreasing the pulse reflectively [3] . Mesatonum was injected intraperitoneally in the dose of 1 mkg/kg [8, 9] . The observation time of animals after Mesatonum injection lasted for 10 minutes.
In total, three experimental groups were formed (each group consisted of 6 animals).
Group 1 -the intact animals injected with Mesatonum only.
Group 2 -the positive control (a single intragastrical dose of peryndopril + Mesatonum in 1 hour).
"Prestarium" tablets (the active substance -4 mg of perindopril) produced by "Servier's Laboratory" company, France was used as a reference drug. The total mass of a tablet is 90 mg. Dosing was carried out based on the active component. Since the maximum therapeutic dose for human equals 0.15 mg/kg, the extrapolated dose of 1.5 mg/kg was calculated for rats.
Group 3 -the chemopyrone substance in the dose of 10 mg/kg + Mesatonum in 1 hour.
During the research with the help of a RM-6000 polygraph (Japan) the ATS and ATD indices of non-anesthetized animals were registered. The rats were placed into special cages-cases of a transparent plastic. The cuff and transducer were put on the tail. Automatically, the pressure was given into the cuff, and the value of the external pressure was determined when the transducer stopped registering the pulse vibrations [1] .
The comparative effectiveness in the groups was estimated according to several indices [4, 6, 7, 8 ]:
• Systolic arterial pressure.
• Diastolic arterial pressure.
The hypotensive activity was examined when reducing the arterial pressure by 25 MmHg and more.
Experiments on animals were conducted according to the Council Directive 2010/63/EU of 22 September 2010 on the protection of animals used for scientific purposes.
The results of the studies were processed in accordance with the Van der Waerden's criterion (SW package Statistica 6).
Results and Discussion
Introduction of Mesatonum to the group of intact animals accompanied with a rapid development of hypertension -in all cases the increase of systolic (by an average of 80 MmHg) and diastolic (by an average of 40 MmHg) arterial pressure was observed. At the same time it was determined that the level of АТS was 212± ±8.5 MmHg, and АТD 125±7.6 MmHg. The effect reached the maximum on the 10-th min of observation and equaled 60-47% of the baseline values.
Prophylactic introduction of perindopril in the group of animals with Mesatonum-induced hypertension within the time of observation prevented the arterial pressure rising and equaled: АТS 138±6.3 MmHg, АТD 81.83± ±1.24 MmHg ( Table 1) .
Injection of chemopyrone in the dose of 10 mg/kg on the model of Mesatonum-induced hypertension presumably prevents increasing arterial pressure. The maximum effect is observed on the 10-th min and equals 64-62% compared to the group of intact animals.
As the data presented in Table 2 testify with the prophylactic use of the chemopyrone substance no significant increase of systolic and diastolic pressure was observed. It indirectly reflects a pronounced and prolonged hypotensive effect in this dose. Significant distinctions compared to perindopril were not observed as well. CONCLUSIONS 1. On the model of Mesatonum-induced hypertension the chemopyrone substance has revealed the expressed hypotensive activity, considerably reducing the level of systolic and diastolic arterial pressure.
2. The data obtained allow to consider the chemopyrone substance as a promising chemical compound for creating a medicine on its basis for hypertensive states correction under conditions of prophylactic application. 
